These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 15529346

  • 21. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95.
    Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dörner T.
    Arthritis Rheum; 2008 Jun; 58(6):1762-73. PubMed ID: 18512812
    [Abstract] [Full Text] [Related]

  • 22. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after therapeutic B-cell depletion.
    Sfikakis PP, Karali V, Lilakos K, Georgiou G, Panayiotidis P.
    Clin Immunol; 2009 Jul; 132(1):19-31. PubMed ID: 19345151
    [Abstract] [Full Text] [Related]

  • 23. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis.
    Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP.
    Arthritis Rheum; 2006 Aug; 54(8):2377-86. PubMed ID: 16869000
    [Abstract] [Full Text] [Related]

  • 24. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [Abstract] [Full Text] [Related]

  • 25. Peripheral circulating activated b-cell populations are associated with nephritis and disease activity in patients with systemic lupus erythematosus.
    Dolff S, Wilde B, Patschan S, Dürig J, Specker C, Philipp T, Kribben A, Witzke O.
    Scand J Immunol; 2007 Nov; 66(5):584-90. PubMed ID: 17868260
    [Abstract] [Full Text] [Related]

  • 26. Depletion of peripheral blood B cells with Rituximab and phenotype characterization of the recovering population in a patient with follicular lymphoma.
    Abulayha AM, Tabal SA, Shawesh EI, Elbasir MA, Elbanani AS, Lamami YM, Bredan A.
    Leuk Res; 2010 Mar; 34(3):307-11. PubMed ID: 19580998
    [Abstract] [Full Text] [Related]

  • 27. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.
    Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM.
    Arthritis Rheum; 2003 Dec; 48(12):3475-86. PubMed ID: 14673998
    [Abstract] [Full Text] [Related]

  • 28. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.
    Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC.
    Arthritis Rheum; 2006 Nov; 54(11):3612-22. PubMed ID: 17075806
    [Abstract] [Full Text] [Related]

  • 29. Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells.
    Devi BS, Van Noordin S, Krausz T, Davies KA.
    J Autoimmun; 1998 Oct; 11(5):471-5. PubMed ID: 9802931
    [Abstract] [Full Text] [Related]

  • 30. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process.
    Papadimitraki ED, Choulaki C, Koutala E, Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD, Mamalaki C, Sidiropoulos P, Boumpas DT.
    Arthritis Rheum; 2006 Nov; 54(11):3601-11. PubMed ID: 17075805
    [Abstract] [Full Text] [Related]

  • 31. A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery.
    Sutter JA, Kwan-Morley J, Dunham J, Du YZ, Kamoun M, Albert D, Eisenberg RA, Luning Prak ET.
    Clin Immunol; 2008 Mar; 126(3):282-90. PubMed ID: 18226586
    [Abstract] [Full Text] [Related]

  • 32. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.
    Roll P, Dörner T, Tony HP.
    Arthritis Rheum; 2008 Jun; 58(6):1566-75. PubMed ID: 18512772
    [Abstract] [Full Text] [Related]

  • 33. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
    Pers JO, Devauchelle V, Daridon C, Bendaoud B, Le Berre R, Bordron A, Hutin P, Renaudineau Y, Dueymes M, Loisel S, Berthou C, Saraux A, Youinou P.
    Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
    [Abstract] [Full Text] [Related]

  • 34. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group.
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [Abstract] [Full Text] [Related]

  • 35. Effects of anti-CD154 treatment on B cells in murine systemic lupus erythematosus.
    Wang X, Huang W, Schiffer LE, Mihara M, Akkerman A, Hiromatsu K, Davidson A.
    Arthritis Rheum; 2003 Feb; 48(2):495-506. PubMed ID: 12571860
    [Abstract] [Full Text] [Related]

  • 36. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody.
    Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD.
    Hum Antibodies; 2004 Feb; 13(3):55-62. PubMed ID: 15598985
    [Abstract] [Full Text] [Related]

  • 37. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S, Nakano S, Watanabe T, Tamayama Y, Mitsuo A, Nakiri Y, Suzuki J, Nozawa K, Amano H, Tokano Y, Kobata T, Takasaki Y.
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [Abstract] [Full Text] [Related]

  • 38. Up-regulation of cellular FLICE-inhibitory protein in peripheral blood B lymphocytes in patients with systemic lupus erythematosus is associated with clinical characteristics.
    Tao J, Dong J, Li Y, Liu YQ, Yang J, Wu Y, Li L, Shen GX, Tan ZJ, Tu YT.
    J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):433-7. PubMed ID: 19335730
    [Abstract] [Full Text] [Related]

  • 39. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
    Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.
    Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
    [Abstract] [Full Text] [Related]

  • 40. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
    Tew GW, Rabbee N, Wolslegel K, Hsieh HJ, Monroe JG, Behrens TW, Brunetta PG, Keir ME.
    Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.